Bevacizumab (400 mg)

admin — Wed, 18 Feb 2026 10:55:11 +0000

Overview: Rituximab 500 mg Injection contains Rituximab (500 mg) and is a prescription monoclonal antibody targeted therapy used in the treatment of certain types of non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL) and some autoimmune conditions by binding to the CD20 receptor on B-cells and promoting their destruction. Key Benefits: – Targets CD20 positive B-cell malignancies to improve treatment outcomes – Used in combination therapy regimens for lymphoma and CLL – Helps reduce disease progression in select autoimmune disorders Composition: Rituximab (500 mg) How It Works: Rituximab is a chimeric monoclonal antibody that binds to the CD20 antigen on B-lymphocytes, leading to cell lysis through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, thereby reducing malignant or autoreactive B-cells. Usage Instructions: – Administer only under the supervision of qualified healthcare professionals via intravenous infusion – Follow the prescribed dosage schedule exactly for best results – Not for self-administration Side Effects: – Infusion-related reactions including fever, chills, and rigors – Nausea, headache, fatigue – Low blood cell counts increasing risk of infection Precautions: – Pre-medication with antihistamines and corticosteroids may be advised to reduce infusion reactions – Monitor blood counts, liver function and infection markers regularly – Not recommended during pregnancy or breastfeeding unless clearly advised by a physician Storage Instructions: – Store refrigerated between 2-8°C, protect from light, do not freeze Manufacturer: Generic Pharmaceuticals Disclaimer: To be sold by retail on the prescription of a registered medical practitioner only.

CLL therapy – Globalstar International

Bevacizumab (400 mg)